50 results about "Muscle actin" patented technology

The invention belongs to the technical field of medicines, and particularly relates to application of sophora alcohol T in preparation of an anti-hepatic fibrosis medicine. The invention provides the application of the sophora alcohol T in preparation of the anti-hepatic fibrosis medicine for the first time, for example, the sophora alcohol T can be applied to preparation of the medicine for preventing or treating hepatic fibrosis. The compound can be used for preparing medicines for inhibiting hepatic stellate cell proliferation or activation, inhibiting fibronectin level rise, inhibiting alpha-smooth muscle actin level rise or inhibiting I-type collagen level rise, and has good patent medicine potential and wide development, transformation and clinical application value and prospect, and the compound can be used for preparing medicines for inhibiting hepatic stellate cell proliferation or activation, inhibiting fibronectin level rise, inhibiting alpha-smooth muscle actin level rise or inhibiting I-type collagen level rise.

The present invention provides compounds, pharmaceutically acceptable compositions thereof, and methods of using the same for the modulation of one or more SWI / SNF-related matrix associated actin dependent regulator of chromatin subfamily A (SMARCA) and / or polybromo-1 (PB-1) protein via ubiquitination and / or degradation by compounds. The compounds are bifunctional molecules that link a cereblon-binding moiety to a ligand that binds SMARCA and / or PB1 proteins.

A phosphodiesterase type 5 inhibitor is used in the preparation of a medicament for resisting fibrotic diseases. Experiments in animal models of ischemia-reperfusion (UIRI)-induced renal fibrosis, unilateral ureteral obstruction (UUO)-caused kidney fibrosis and idiopathic pulmonary fibrosis show that a PDE5 inhibitor such as tadalafil, sildenafil and vardenafil can significantly inhibit the expression of multiple fibrosis iconic proteins such as fibronectin, collagen I, renal injury molecule-1, and α-skeletal muscle actin in UIRI and UUO renal fibrosis lesions, improves glomerulopathy, degree of renal tubular distension, renal interstitial collagen fiber deposition and inflammatory cell infiltration, reduces the fibrotic area within the lesion, and significantly inhibits the progression of renal fibrosis; and the PDE5 inhibitor can significantly improve smooth muscle proliferation and inflammatory cell infiltration in bronchioles and pulmonary arterioles of idiopathic pulmonary fibrosis lesion, improve damage condition of alveolar tissue, and significantly inhibit the progression of pulmonary fibrosis.

The application discloses a marker for determining the severity of IgAN kidney tissue lesions and application thereof, and inventors find that ACTN4, ACADS and COL1A1 are significantly differentially expressed proteins in kidney tissues. The significant down-regulation of ACTN4 may cause the change of actin cytoskeleton of IgAN glomerular podocytes; the significant down-regulation of ACAD may indirectly participate in the occurrence process of abnormal structure and function of IgAN renal tubular epithelial cells by affecting fatty acid metabolism in the cells; and the significant up-regulation of COL1A1 may participate in the accumulation of extracellular matrix in the renal interstitium of IgAN, and play a certain role in promoting the renal interstitial fibrosis. The combination of ACTN4, ACADS and COL1A1 has good prediction efficiency for the diagnosis of the severity of IgAN kidney tissue lesions, and the area under the ROC curve is 0.815, P 0.043. In addition, the immunohistochemical results also confirm the expression trend of the three proteins ACTN4, ACADS and COL1A1 in the corresponding kidney tissue substructures in proteomics.

The present application relates to the technical field of health care products, in particular to a pelvic floor muscle repairing composition containing supermolecular tightening Dropsordry and a preparation method thereof, which comprises the following components in mass fraction: 10-14 parts of protein composition, 20-24 parts of chitosan modified Dropsordry, 5-7 parts of freeze-dried powder of Lactobacillus bulgaricus, 10-12 parts of hyaluronic acid, 6-8 parts of glycine and 15-17 parts of proline; each part of the protein composition comprises 20-30 parts of myosin, 30-34 parts of actin, 5-10 parts of hydrolyzed collagen and 240-280 parts of deionized water. The pelvic floor muscle repairing composition can reduce drug toxicity, reduce the amount of drug administration, continuously supplement the required elements of the body during treatment, and quickly relieve the constipation problem caused by the functional damage of the pelvic floor muscle.

According to the RNA binding protein HuR inhibitor and the anti-fibrosis application thereof, the compound provided by the invention has obvious inhibitory activity on HuR protein, has a good anti-renal fibrosis effect, can obviously reduce protein and mRNA expression levels of fibronectin (FN1) and alpha-smooth muscle actin (alpha-SMA), can improve renal function impairment, and can be used for preparing the anti-fibrosis medicine for treating renal fibrosis. The levels of blood urea nitrogen (BUN) and creatinine (Cr) which are commonly used for evaluating the renal function are reduced, and the compound can be used for preparing the medicine for treating the chronic kidney disease.

This invention provides an organ fibrosis-related micropeptide, OFMP, and its applications. This type of micropeptide, OFMP, is a translational product with endogenous biological activity and stable existence, encoded by an open reading frame (ORF) in a long non-coding RNA. It is the first time that the long non-coding RNA encoding the micropeptide has been found to be significantly related to organ fibrosis and can encode the micropeptide. Synthetic peptides prepared based on the aforementioned OFMP micropeptide show significant inhibitory effects on several key indicators of organ fibrosis, including type I collagen α1 chain gene, α-smooth muscle actin, transforming growth factor β1, and connective tissue growth factor. This indicates that the OFMP micropeptide, the nucleotide sequence (ORF) encoding the micropeptide, and the long non-coding RNA sequence containing the nucleotide sequence have important clinical diagnostic and therapeutic value for organ fibrosis.

Radiolabelled binding agents that specifically bind to F-actin are provided. In particular, the radiolabelled binding agents of the invention exhibit preferential binding for F-actin over G-actin, which enables them to be used in medical and research settings. The invention provides radiolabelled binding agents, medical uses thereof, methods of generating radiolabelled binding agents and kits.

The invention belongs to the cross technical field of cell engineering, nano-drugs and biological manufacturing, and particularly discloses a drug-loaded vesicle based on denucleated cells as well as a preparation method and application of the drug-loaded vesicle. According to the invention, a cell suspension and a cytoskeleton relaxant are co-incubated to relax an actin skeleton and weaken nucleoplasm connection; then loading the treated cell suspension on a multi-layer discontinuous density gradient centrifugal medium, realizing physical separation of cell nucleuses and cytoplasm through high-speed centrifugation according to buoyancy density difference, and collecting components of a specific interface to obtain high-purity denucleated cells with a complete membrane structure; then co-incubating the denucleated cells and ROS response type lipidosome (co-carrying therapeutic siRNA and a sound-sensitive agent Ce6) prepared in advance, so that the lipidosome is wrapped or anchored by a denucleated cell membrane; finally, the composite system is subjected to extrusion treatment through a microporous membrane, the drug-loaded vesicles uniform in particle size and stable in structure are obtained, and the drug-loaded vesicles are suitable for various application scenes such as anti-tumor treatment and RNA vaccine delivery.

The present application relates to a freshness indicator protein related to quality traits of low-temperature stored Siniperca chuatsi, endogenous proteases and applications. The freshness indicator endogenous proteases are related to postmortem proteolysis and meat softening of Siniperca chuatsi, including cathepsin B, cathepsin L and calpain. The freshness indicator proteins are related to quality changes occurring during postmortem cold storage of Siniperca chuatsi, including myoactin 1, myosin binding protein, LDB protein, actin-related protein, etc. The present application determines the change rule of endogenous protease activity of Siniperca chuatsi at different storage stages, and the dynamic influence on muscle proteolysis and muscle degradation of Siniperca chuatsi, and reveals the internal relationship with fish meat sensory quality and processing characteristics, and clearly defines the "critical point" of quality deterioration of Siniperca chuatsi. It provides clear guidance for the control of endogenous enzyme-mediated quality deterioration in the processing and storage process of Siniperca chuatsi.

The invention relates to sesquiterpenoids Oxyphyllene F and Oxyphyllene G which are separated from fructus alpiniae oxyphyllae and application of the sesquiterpenoids Oxyphyllene G. Experimental research finds that the two compounds can inhibit the expression of fibronectin, type I collagen and alpha-smooth muscle actin in rat renal tubular duct epithelial cells induced by TGF-beta1, have anti-renal fibrosis activity, and can be used for preparing anti-renal fibrosis drugs. The fructus alpiniae oxyphyllae can be effectively used for preparing kidney protection drugs, the preparation method is good in reproducibility, the purity of the obtained compound is high, further pharmacological and clinical research on the compound is facilitated, the medicinal value of the fructus alpiniae oxyphyllae is expanded, and the economic and social benefits are huge.

The invention belongs to the technical field of biological medicines, and discloses a deep sea steroid compound, a preparation method thereof and application of the deep sea steroid compound in preparation of medicines for preventing or treating renal fibrosis. The steroid compound is a class of highly oxidized and modified ergoketone compounds, and in some embodiments, the compound has an unusual malonyl substitution at the C-12 position of an ergoketone skeleton. The steroidal compound disclosed by the invention can achieve the effect of inhibiting renal fibrosis by regulating and controlling expression down-regulation of key fibrosis markers, namely alpha-smooth muscle actin (alpha-SMA) and I-type collagen (COL1A1), and has an inhibiting effect on proliferation of TGF-beta1-induced mouse renal fibroblasts; therefore, the compound has a great application prospect in preparation of drugs for preventing or treating renal fibrosis.

The present invention relates to a composition for preventing, alleviating or treating fibrosis, the composition comprising bentonite as an active ingredient. Bentonite is highly effective in reducing a disease activity index, inhibiting shortening of colon length, regulating the expression level of a gene related to intestinal fibrosis, reducing a collagen deposition site in intestinal tissue, reducing the expression level of fibronectin and collagen proteins in intestinal tissue in an intestinal fibrosis animal model induced by dextran sulfate sodium (DSS), and reducing the expression level of ɑ-smooth muscle actin (ɑ-SMA) and collagen proteins in an intestinal fibrosis cell model induced by TGF-β, and is thus expected to be useful as a composition for preventing, alleviating, or treating intestinal fibrosis.

A system and method for distinguishing non-failing from failing cardiac fibroblasts (CFs) using advanced imaging techniques and machine learning (ML). The method involves staining CFs with fluorescent dyes to highlight key cellular components, such as nuclei and actin fibers. Images are analyzed to extract morphological features, which are then processed and normalized. A supervised ML system, trained on labeled CF data, classifies CFs based on phenotypic differences. The system enables accurate diagnosis of heart failure (HF), facilitates screening for therapeutic efficacy, and identifies antifibrotic agents by evaluating changes in CF phenotypes pre- and post-treatment.

The invention belongs to the field of glycoprotein anti-cancer active ingredients, and particularly relates to pleurotus citrinopileatus 93 selenoglycoprotein-I, a preparation method and application thereof and a medicine for resisting pleuroperitoneal visceral cancers, the pleurotus citrinopileatus 93 selenoglycoprotein-I is protein containing selenium bonds and polysaccharide chains, and the polysaccharide chains are sugar unit fragments with the structure shown in the formula 1; the protein part comprises protein for driving a protein motion structural domain, actin and valyl-tRNA synthetase; hydroxyl in the polysaccharide is connected with at least one amino acid of aspartic acid, valine, glutamic acid, arginine, lysine and serine in the protein through a hydrogen bond; the selenium bond comprises at least one of Se = O and Se-C-O. The invention develops brand-new selenoglycoprotein which can accidentally inhibit the activity of pleuroperitoneal viscera cancer cells with high specificity.

The application discloses a kind of core-shell structure sequential drug release microneedle and its preparation method and application, the microneedle structure includes: PAA backing layer;And the needle body of the one side surface of PAA backing layer is arranged;The needle body is core-shell structure, the outer layer of the core-shell structure is the silk fibroin of loading SeS2, the inner layer of the core-shell structure is the PAA of loading IR780 and NaHCO3.By core-shell structure design, the slow release characteristics of silk fibroin are combined with the quick release characteristics of PAA gas production trigger, realize the time sequence difference release of two drugs, sequential drug administration simultaneously induce selenium poisoning (SEPHS2, SELS, GPX4 down-regulation) and double sulfur death (actin crimp), synergistic antitumor effect is better than synchronous administration.

This invention belongs to the field of biomedicine, specifically relating to the application of APOL2 (Apolipoprotein L2) inhibitors in the preparation of products for treating liver fibrosis. The inventors isolated a series of natural tetrodopane-type diterpenes from *Euphorbia pekinensis*, a plant in the Euphorbiaceae family. Anti-liver fibrosis-related activity tests on this series of diterpenes revealed that they significantly inhibited the expression of fibronectin, type I collagen, and α-smooth muscle actin in LX-2 cells. In animal studies, their therapeutic effect was superior to that of pirfenidone, a phase II clinical trial drug for treating liver fibrosis, and they showed no significant toxicity. Mechanistic studies showed that TD1 is an APOL2 inhibitor, and knocking out APOL2 protein in vivo can alleviate the progression of liver fibrosis. In summary, this series of tetrodopane-type diterpenes, especially TD1, shows promise as a candidate drug for treating liver fibrosis and provides a new target for researching novel drugs for treating liver fibrosis.

The invention provides application of 73rd histidine methylation of serum actin as a marker in preparation of a reagent for assisting early prognosis evaluation of sepsis, and belongs to the technical field of biomarkers. Tests show that the 73rd site histidine of serum actin is subjected to methylation modification, and the differences among a Control group, a Survivor group and a Non Survivor group are remarkable; the secondary spectrum of the target peptide fragment shows that the peptide spectrum matching effect of the modified peptide fragment is good, and the modification identification is credible; and the area under the ROC curve and the 95% confidence interval are 73.56% (60.17%-82.68%). Under the optimal cutoff value of 30.29, the sensitivity is 0.792, the specificity is 0.639, the positive predicted value is 0.656, the negative predicted value is 0.780, the positive likelihood ratio is 2.198, and the negative likelihood ratio is 0.325. Therefore, the 73 histidine methylation of serum actin is an independent predictive factor of sepsis prognosis, can be used as a reliable and potential biomarker for early prognosis evaluation of sepsis, and has important clinical application value.

The invention relates to the technical field of cell therapy, and particularly discloses a repairable fibroblast preparation for treating pelvic organ prolapse. The active ingredients of the preparation are fibroblasts which highly express HAS1, POLR3G and DDR2 at the same time and do not express alpha-smooth muscle actin, and the preparation is compatible with pharmaceutic adjuvants such as normal saline, human serum albumin and dimethyl sulfoxide. The dosage form of the composition comprises an injection and a gel containing a hyaluronic acid matrix. The preparation method comprises the following steps: performing enzymolysis treatment to obtain primary cells, promoting repair phenotypic differentiation through estrogen induction, purifying target cells by adopting a fluorescence labeling flow sorting technology, and performing amplification in a serum-free culture medium to prepare a final preparation. According to the preparation, through the synergistic effect of fibroblasts and pericytes and the perivascular positioning characteristic, targeted repair of pelvic floor supporting tissue can be achieved; according to the preparation method, the cell phenotype stability and the preparation reproducibility are ensured by optimizing process parameters and quality control standards.

This invention belongs to the field of biomedical technology, and specifically relates to the application of berberine in the preparation of drugs for treating asthma. This invention, through experimental demonstration, reveals for the first time that berberine can effectively target the actin-binding protein Ezrin and has a significant function in relaxing airway smooth muscle, making it suitable for the preparation of drugs for treating asthma and possessing broad application prospects.

The invention provides a method for preparing myofibrillar protein gel based on low-temperature sol agar. The method comprises the following steps: preparing myofibrillar protein; dispersing low-temperature sol agar in a sodium chloride solution, and melting to obtain a low-temperature sol agar solution; adding the low-temperature sol agar solution into the myofibrillar protein to obtain mixed sol; centrifuging the mixed sol to remove bubbles; putting the bubble-removed mixed sol into a water bath, and cooking to form heat-conducting gel; and refrigerating the gel at low temperature overnight to obtain the myofibrillar protein gel. According to the method, low-temperature sol agar is dissolved in myofibrillar protein, so that the cooking loss of the pork myofibrillar protein gel is reduced and the aggregation of the myofibrillar protein is promoted at the temperature of 60-80 DEG C, actin of the myofibrillar protein can be protected at the temperature of 78-80 DEG C and is not degraded due to the influence of temperature, and meanwhile, the nutritional characteristics and the gel strength of the pork myofibrillar protein gel are not changed.

The application discloses an indole alkaloid compound, a preparation method and application thereof in preparation of a medicine for treating chronic kidney disease, and the structure of the indole alkaloid compound is shown as formula I. The new indole alkaloid compound is extracted from fruits of a plant for the first time, the compound can significantly reverse the increase of alpha-smooth muscle actin, type I collagen and vimentin expression in HK-2 cells induced by TGF-beta, and the compound shown as formula I has a drug development potential for preventing or treating chronic kidney disease, in particular, anti-kidney fibrosis, at a concentration of 10 muM.

The present invention provides compounds, pharmaceutically acceptable compositions thereof, and methods of using the same for the modulation of one or more SWI / SNF-related matrix associated actin dependent regulator of chromatin subfamily A (SMARCA) and / or polybromo-1 (PB-1) protein via ubiqitination and / or degradation by compounds. The compounds are bifunctional molecules that link a cereblon-binding moiety to a ligand that binds SMARCA and / or PB1 proteins.

The present invention is a method to improve physical-sports performance, reduce fatigue, combat physical-sports aging, and to cure and prevent physical injuries, based on an effective dose of glycine, L-proline, L-lysine, L-aspartic acid (or L-aspartate, citric acid, or citrate), and vitamin C. The method is based on the limitations and subsequent conditions of the metabolism in three aspects: (1) the synthesis of ATP in mitochondria, dependent on the Krebs cycle; (2) the synthesis of proteins of the passive mechanical system (collagen and elastin); (3) the mechanism of muscle contraction in actin-myosin interaction cross-bridge cycles. while ensuring that the diet must contain a sufficient amount of protein.

The invention belongs to the technical field of medicines, and particularly relates to application of sophora alcohol O in preparation of anti-hepatic fibrosis medicines. The invention provides the application of the sophora alcohol O in preparing the anti-hepatic fibrosis medicine for the first time, for example, the sophora alcohol O can be applied to preparing the medicine for preventing or treating hepatic cell fibrosis and mouse hepatic tissue fibrosis. The compound also can be used for preparing medicines for inhibiting proliferation or activation of hepatic stellate cells, inhibiting hepatic fibrosis in a living body, inhibiting level rise of fibronectin (FN), inhibiting level rise of alpha-smooth muscle actin (alpha-SMA), inhibiting level rise of type I collagen (collagen I, collagen II, collagen III, collagen III, collagen IV and the like), and inhibiting liver fibrosis in a living body, level rise of fibronectin (FN, FN), level rise of alpha-smooth muscle actin (alpha-SMA) and level rise of alpha-SMA. The invention relates to a medicine for inhibiting the level rise of alanine aminotransferase (ALT) in mouse serum, inhibiting the level rise of aspartate aminotransferase (AST) in mouse serum and inhibiting the level rise of hydroxyproline (HYP) in mouse liver tissue, and the medicine has good patent medicine potential and wide development, transformation and clinical application values and prospects.

The invention relates to a modulus-maintaining water-retaining hydrogel dressing and a preparation method thereof.The mechanical property of hydrogel is enhanced by forming a physical cross-linked and chemical cross-linked network, and all components form a semi-interpenetrating network with physical cross-linked points through hydrogen bonds; the lysine polymer or the derivative thereof is added into the reactive polymer in an epoxy ring opening manner in a chemical grafting manner, chemical crosslinking points are increased, freezing and unfreezing are performed in an aqueous solution to enhance hydrogen-bond interaction, and water in the reactive polymer can be effectively prevented from being lost. The method is simple in preparation process, hydrogel with different gradient strengths can be obtained, and the dressing is excellent in water retention performance in the using process, has the capacity of maintaining the initial modulus on the wound surface for a long time and can retain the lysine polymer and the derivative thereof for a long time, so that long-acting antibacterial and long-acting wound healing are achieved. The low-modulus dressing significantly reduces proliferation of smooth muscle actin and I-type collagen, and promotes scar-free healing of wounds. The dressing disclosed by the invention is high in biological safety, strong in reproducibility, simple and convenient in process and huge in application potential.

The application discloses a sugar metabolism regulation type nanomaterial, a preparation method thereof and application thereof in anti-tumor treatment, and belongs to the technical field of tumor pharmaceutical preparations. The sugar metabolism regulation type nanomaterial provided by the application takes a double sulfur death / iron death inducer loaded with a chemotherapeutic drug as an inner core, and is surface-modified with a NO donor conjugate; the sugar metabolism regulator is a polyphenol compound, and the double sulfur death / iron death inducer is a metal-phenolic network, which can interfere with sugar metabolism, reduce NADPH production, thereby causing cystine accumulation and actin cytoskeleton destruction to induce double sulfur death; and inhibit the synthesis of GSH to enhance the iron death effect. In addition to the direct tumor killing effect, the nanomaterial can also reverse the immunosuppressive tumor microenvironment, realizing synergistic inhibition on tumor treatment. The application provides a new strategy with good anti-tumor effect and application potential for cancer combined treatment.

The invention belongs to the technical field of gene therapy, and particularly relates to application of an inhibitor of a targeted Xirp2 gene in preparation of a medicine for preventing or treating myocardial fibrosis. In order to determine the effect of the actin binding protein Xirp2 in the cardiac hypertrophy process caused by pathological matrix hardness-induced myocardial cell hypertrophy and pressure overload, the invention provides application of an inhibitor of a targeted Xirp2 gene in preparation of a medicine for preventing or treating myocardial fibrosis. The inhibitor is siRNA of which the nucleotide sequence is shown as SEQ ID NO: 1-3 or shRNA of which the nucleotide sequence is shown as SEQ ID NO: 4. The invention finds that Xirp2 is related to myocardial hypertrophy caused by myocardial cell hypertrophy induced by pathological matrix hardness and myocardial hypertrophy caused by pressure overload for the first time, and after expression of Xirp2 is knocked down in vivo and in vitro, myocardial hypertrophy can be relieved. Therefore, the invention develops a new application of the inhibitor targeting the Xirp2 gene, develops a new medicine and a new treatment mode for myocardial fibrosis, and has great significance.